NCT00674310View on ClinicalTrials.gov

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions

Parkinson's DiseaseRestless Leg Syndrome

Interventions

DRUG

Ropinirole Hydrochloride

Restless Leg Syndrome

All Listed Sponsors

lead

Roxane Laboratories

INDUSTRY

NCT00674310 - A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions | Biotech Hunter | Biotech Hunter